Original Post on Genengnews By: Alex Philippidis According to CEO Jeff Galvin, the cell and gene therapy developer hopes its Addimmune spinout will pick up where AGT leaves off in developing a one-time treatment for HIV, in light of positive early data.   A leading developer of gene and cell therapies is spinning out a…

Original Post on Precision Medicine Online By: Jessica Kim Cohen   NEW YORK – American Gene Technologies (AGT), a 15-year-old privately held biotech firm, is spinning off its HIV drug development program into a separate company that will exclusively focus on advancing therapeutics against the AIDS-causing virus. The new company, Addimmune, will separate from AGT within a year…

Original post on Poz.com By Trent Straube Sexual molestation as a child, an abusive father, the foster care system, violent street gangs, an HIV diagnosis as a teenager. “Anything you can think of that’s bad, I’ve been through it,” says Latina HIV advocate Maria Mejia in an episode of The Cure Chronicles. Despite her challenges, Mejia’s story is one of…

The Biotech Project podcast welcomes CEO and Founder of American Gene Technologies®, Jeff Galvin, onto the show to discuss the past, present, and future of the company’s mission to use the power of gene therapy to relieve human suffering from serious diseases. Hosts Scott J Resnik, MBA, NYS EMT-CC, and John Walsh, MD, sit down…

Raj Natarajan, host of ShareTreck, goes behind the scenes with Jeff Galvin, Founder and CEO of American Gene™ in this compelling interview to learn how gene therapy works, and what it means for people with deadly diseases, as well as how it will impact the current pharmaceutical landscape. The company is currently in the midst…

Have a listen. https://www.americangene.com/wp-content/uploads/2022/09/testing-a-gene-therapy-to-cure-hiv-fundamentally-change-healthcare-with-jeff-galvin-of-american-gene-technologies.mp3 From Lab to Launch by Qualio Jeff is the CEO and founder of American Gene Technologies®. He earned his BA degree in Economics from Harvard and has more than 30 years of business and entrepreneurial experience including founder or executive positions at various Silicon Valley startups. Following his startup experience, he…

Original post on queerty.com By David Hudson   The trial of a potential HIV cure is underway. The scientists involved hope for initial results toward the end of the year. One of them also has stark warnings about the threat to humanity of future pandemics. He believes that, as seen with HIV and monkeypox, gay men…

Download the Report The exact origins of Human Immunodeficiency Virus (HIV) are not precisely known, but researchers theorize that the virus may have originated in chimpanzees,1and then crossed to humans via blood borne pathway. It is not radically different from many of the other retroviruses that exist in nature such as the avian sarcoma virus…

Original post on citybiz.co American Gene Technologies, a clinical-stage biotechnology company, has appointed Jeff Boyle, PhD as chief science officer. Dr. Boyle comes to the post with deep biotechnology expertise which will help further accelerate the company’s FDA-approved HIV gene therapy clinical trial that expects to see first indications of efficacy in Q3, as well as continue…

Original post on WJLA.com We have an update in what developers hope will be an HIV cure, a story we’ve been following for more than a year now.   A Maryland-based company says its early data in three patients shows their altered cells are not getting infected, maintaining characteristics that show they’re ready to fight…

Original post on WJLA.com   The efforts to find a functional cure for HIV are speeding up for one Maryland company after the Data Safety and Monitoring Board found no serious, adverse events with the third patient, as was the case for the previous two, American Gene Technologies® announced.   “One patient can be lucky. Two…

Original post on ABC7 News   ROCKVILLE, Md. (7News) — There’s more good news in the fight to cure HIV.   American Gene Technologies says its clinical trial has resulted in more patients with substantial increases in virus-specific T-cells with immunity against HIV.   Progress in HIV cure: AGT™ hopes to have a ‘functionally cured patient…